Cardionovum

Be up
to date.

Latest press release

A Decade of Innovation: Matteo Tozzi's Insights on Drug-Coated Balloons in Vascular Surgery

Prof. Matteo Tozzi (Varese, Italy) spoke to Vascular News about his extensive experience with drug-coated balloons (DCBs) in vascular access, particularly the Aperto® OTW DCB by Cardionovum®.

Having used over 600 DCBs in the past decade, Tozzi emphasized the superior efficacy of Aperto® OTW compared to plain balloon angioplasty (POBA).

To address the lack of economic data, he has initiated an analysis to evaluate the cost-effectiveness of DCBs in treating vascular access failure: based on the findings of his study named Aperto 600, Tozzi advocates for DCBs to be considered a “first-line treatment” for stenosis and vascular access failure in haemodialysis patients.

Learn more >>

“Aperto® DCB: A Glimpse of the Future Today” Webinar

If you were unable to attend the webinar "Aperto® DCB: A Glimpse of the Future Today,” you can still view the session.

 

Please click here to access the video.

 

Thanks to Dr. Kitrou from Patras, Prof. Tozzi from Varese, and Dr. Shahverdyan from Hamburg, you will have the opportunity to:

 

  • Gain a comprehensive overview of the DCB’s role in the Vascular Access landscape today and in the future;
  • Receive the latest clinical update on Aperto® and its cost-benefit implications;
  • Participate in a practical session with a discussion on challenging cases.

Learn more >>

The XLIMIT Trial: XLIMUS® DES Shows Non-Inferiority to Synergy™ DES

Dr. Testa (Milan, Italy) discusses the results of the XLIMIT Trial with Radcliffe at the EuroPCR 2024 congress in Paris, France.

 

In this video interview, Dr. Testa explains the technology behind the XLIMUS® drug-eluting stent (Cardionovum®) and its benefits. He also reviews the XLIMIT Trial, detailing the study design, selection criteria, and clinical outcomes.

 

Specifically, the 6 to 9 months follow-up results showed that the XLIMUS® DES was comparable to the Synergy™ DES on both primary endpoints (in-stent neointimal percent volume obstruction and in-stent neointimal volume). No difference was also found with respect to the secondary OCT endpoints as well as for clinical endpoints.

 

The study results confirm that the biological interaction of the XLIMUS® and Synergy™ DES with the coronary artery is comparable, and that translates in very reassuring OCT parameters at follow-up: as such, the XLIMUS® DES is non-inferior to the Synergy™ DES.

Learn more >>

The HYPER Study Findings: Hybrid Approach with Restore® DEB Shows Promising Long-Term Results

Dott. Ielasi (Milan, Italy) speaks to Radcliffe at EuroPCR 2024 congress held in Paris (France) about the results of the Hyper Study 2-years Follow-up.

 

In this video interview, Dr. Ielasi explains the technology behind the Restore® drug-coated balloon (Cardionovum®) and its advantages. Furthermore, he offers a comprehensive analysis of the HYPER Study, elucidating its methodology, participant selection criteria, and clinical outcomes.

 

Specifically, the 1-year outcomes revealed that DoCE was 3.7%. Subsequently, an extensive 2-year follow-up demonstrated a DoCE rate of 4.6%, maintaining stability up to the 3-year analysis.

 

In conclusion, the HYPER Study demonstrated that the hybrid approach combining a drug eluting stent with the Restore® DEB is not only feasible but also associated with very high procedural success and a remarkably low 1-year DoCE rate. These favourable results remain consistent over the 3-year follow-up period.

Learn more >>

Dr. Lichtenberg discusses about Aperto® DCB in the Archives of Internal Medicine Research journal

Cardionovum® is present in the Archives of Internal Medicine Research (ISSN: 2688-5654) in the article entitled “Drug Coated Balloon Angioplasty for Dysfunctional Arteriovenous Fistula: A New Standard-of-Care in the Horizon?”.

 

In this recent article, Dr. Lichtenberg unveils the role of DCBs in Vascular Access Management, and an entire chapter is devoted to our Aperto® OTW drug coated balloon with an extensive overview of its main technical features and clinical results.

 

The Archives of Internal Medicine Research (ISSN: 2688-5654) is an open access peer-reviewed journal providing innovative and clinically relevant research platform for physicians, practitioners, pathologists, pharmacologist and students in general internal medicine and internal medicine subspecialties with an Impact Factor 3.6.

Learn more >>

Cardionovum® Recognized Among Europe's Top 10 Cardiovascular Solutions Companies in 2023

We are glad to announce Cardionovum®'s prestigious recognition as one of the Top 10 Cardiovascular Solutions Companies in Europe for 2023 by MedTech Outlook.

 

This acknowledgment reflects our unwavering commitment to innovation and excellence within the field of cardiovascular solutions.

Being included in this list is a proof to our Team's dedication and the impact of our pioneering technologies.

 

In addition, we are honored to be present in the November edition of MedTech Outlook magazine, providing an in-depth article that delves into our contributions in driving innovation to improve patients' lives.

Learn more >>

Upcoming events

Cardionovum® at EuroPCR 2025

Cardionovum® is pleased to invite you to visit us at booth #M4.

Location:

Palais des Congrès de Paris
2 Place Porte Maillot
Paris
France

Date: May 20, 2025–May 23, 2025

Latest events

Cardionovum® at LINC 2023

Cardionovum® is pleased to invite you to visit us at booth #19B

Location:

Leipziger Messe GmbH,
Hall 2, Messe-Allee 1,
04356, Leipzig,
Germany

Date: June 06, 2023–June 10, 2023

Cardionovum® at EuroPCR 2023

Cardionovum® is pleased to invite you to visit us at booth #M14

Location:

Palais des congrès de Paris
2 Pl. de la Prte Maillot,
75017 Paris,
France

Date: May 16, 2023–May 20, 2023

Cardionovum® at 31th Erfurter Dialysefachtagung 2023

Cardionovum® is pleased to invite you to visit us at booth #28

Location:

Kaisersaal
Futterstr. 15/16,
99084 Erfurt, Germany

Date: May 04, 2023–May 06, 2023

go top